Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Case Report Volume 6 Issue 1

Huge Adrenocortical Carcinoma: Case Report and Literature Review

Maatougui Jasser1*, Raboudi Mehdi1, Ben Rejeb Nedhir1, Besrour Chayma1,2, Gargouri Faten3, Ramzi Khiari1, Ouertani Haroun2 and Ghozzi Samir1

1Department of Urology, Military Hospital of Tunis, Tunis, Tunisia
2Department of Endocrinology, Military Hospital of Tunis, Tunis, Tunisia
3Department of Pathology, Military Hospital of Tunis, Tunis, Tunisia

*Corresponding Author: Maatougui Jasser, Department of Urology, Military Hospital of Tunis, Tunis, Tunisia.

Received: November 22, 2021; Published: December 15, 2021

Abstract

Adrenocortical carcinoma is a rare entity. We report a case of a 47-year-old male with abdominal pain. without classical tumor symptoms. Computed tomography revealed a left adrenal mass measuring 17 cm. Hormonal evaluation was negative. Open left adrenalectomy was performed by sub-costal approach. Diagnosis of adrenocortical carcinoma was established by pathology. Metastatic workup was negative. The patient has been followed regularly with no recurrence for one year. Adrenocortical carcinoma is a challenge. Surgery is the main treatment.

Keywords: Adrenocortical Carcinoma; Adrenalectomy; Mitotane

References

  1. Almarzouq A., et al. “Giant nonfunctioning adrenocortical carcinoma: a case report and review of the literature”. BMC Research Notes 31 (2014): 7.
  2. Patel VV., et al. “Giant non-functioning adrenocortical carcinoma: A rare childhood tumor”. Indian Journal of Medical and Paediatric Oncology 2 (2010): 65-68.
  3. Vassilopoulou-Sellin R and Schultz PN. “Adrenocortical carcinoma. Clinical outcome at the end of the 20th century”. Cancer 92 (2021): 1113.
  4. Dehner LP and Hill DA. “Adrenal cortical neoplasms in children: Why so many carcinomas and yet so many survivors?” Pediatric and Developmental Pathology 12 (2009): 284-291.
  5. Angeli A., et al. “Adrenal incidentaloma: An overview of clinical and epidemiological data from the National Italian Study Group”. Hormone Research 47 (1997): 279-283.
  6. Kapoor A., et al. “Guidelines for the Management of the Incidentally Discovered Adrenal Mass”. Canadian Urological Association Journal 4 (2011): 241-247.
  7. Zhou Z., et al. “Multidisciplinary team therapy for left giant adrenocortical carcinoma: A case report”. World Journal of Clinical Cases 20 (2021): 5737-5743.
  8. Schteingart DE., et al. “Management of patients with adrenal cancer: recommendations of an international consensus conference”. Endocrine-Related Cancer 12 (2005): 667.
  9. Kiesewetter B., et al. “Management of adrenocortical carcinoma: are we making progress?”. Therapeutic Advances in Medical Oncology 13 (2021): 17588359211038409.
  10. Mytareli C., et al. “The Diagnostic, Prognostic and Therapeutic Role of miRNAs in Adrenocortical Carcinoma: A Systematic Review”. Biomedicines 11 (2021): 1501.

Citation

Citation: Maatougui Jasser., et al. “Huge Adrenocortical Carcinoma: Case Report and Literature Review”.Acta Scientific Medical Sciences 6.1 (2022): 151-153.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In





News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US